Freedom of Information request on internal emails relating to Post Finasteride Syndrome caused by any 5-Alpha-Reductase Inhibitor medicines (FOI 22/690)
Published 27 March 2023
© Crown copyright 2023
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/freedom-of-information-responses-from-the-mhra-week-commencing-6-june-2022/freedom-of-information-request-on-internal-emails-relating-to-post-finasteride-syndrome-caused-by-any-5-alpha-reductase-inhibitor-medicines-foi-2269
FOI 22/690
10th June 2022
Dear
Thank you of your email dated 10th May 2022, where you requested:
“All internal emails in regards to a syndrome known as “Post Finasteride Syndrome (PFS)” caused by any 5-Alpha-Reductase Inhibitor medicines on behalf of the freedom of information act (FOAI) from the dates of 2001 to January 2022.”
We are pleased to inform you that most of the information which you have requested has already been released as part of a previous FOI request (21/630) and can be accessed using the link below:
In addition to this we have performed another search of our records for your requested time period and a further four emails are attached. Redactions have been made under Section 40 of the FOI Act, the names of employees below the grade of Senior Civil Servant (SCS) have been withheld. This is because they are normally not responsible for high profile work and would not reasonably expect their personal details to be in the public domain. As a result, the releasing of their names would not, in our view, be fair or reasonable. We have also made redactions under Section 41 – information provided in confidence. Information provided to us in confidence, with the expectation that it will not be released, is exempt from disclosure under the FOI Act.
I hope the information provided is helpful, but if you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of this response; and can be addressed to this email address.
Yours sincerely,
FOI Team,
Vigilance and Risk Management of Medicines Division